Wednesday, October 28, 2009 11:01:14 PM
Press Release
Source: Cumberland Pharmaceuticals Inc.
On 10:00 am EDT, Tuesday October 27, 2009
Companies:Cumberland Pharmaceuticals, Inc.
NASHVILLE, Tenn., Oct. 27 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX - News) announced today that it will report third quarter 2009 financial results before the market opens on Tuesday, November 10, 2009. A conference call and live Internet webcast will be held on Tuesday, November 10, 2009 at 10:00 a.m. Eastern Time to discuss the results.
To participate on the call, please dial 888-417-8462 (for U.S. callers) or 719-457-2552 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 888-203-1112 (for U.S. callers) or 719-457-0820 (for international callers). The passcode for the rebroadcast is 9695498. The live webcast and rebroadcast can be accessed via Cumberland Pharmaceuticals' website at http://investor.shareholder.com/cpix/events.cfm.
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote® for the treatment of acetaminophen poisoning and Kristalose®, a prescription laxative. The Company also recently launched Caldolor®, the first injectable treatment for pain and fever available in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed its initial public offering of common stock in August 2009.
For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com
Recent CPIX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 03:31:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:29:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 09:42:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:03:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 09:07:25 PM
- Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 • PR Newswire (US) • 08/06/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:16:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:14:54 PM
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS • PR Newswire (US) • 07/30/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:37:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:14:15 PM
- Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update • PR Newswire (US) • 05/07/2024 08:05:00 PM
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS • PR Newswire (US) • 04/30/2024 08:05:00 PM
- NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS • PR Newswire (US) • 04/02/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:10:30 PM
- Cumberland Pharmaceuticals Reports Annual 2023 Financial Results • PR Newswire (US) • 03/05/2024 09:05:00 PM
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS • PR Newswire (US) • 02/27/2024 09:05:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/09/2024 10:27:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:11:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:10:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:08:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/27/2023 05:15:30 AM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM